ENZ Fundamental Analysis - ENZO BIOCHEM INC

Name: ENZO BIOCHEM INC (ENZ) Stock
Brand: ENZO BIOCHEM INC
Rating: 3.5 (3 reviews)

Fundamental Rating

ENZ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. The financial health of ENZ is average, but there are quite some concerns on its profitability. ENZ does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ENZ had negative earnings in the past year.

In the past year ENZ has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: ENZ reported negative net income in multiple years.

In the past 5 years ENZ reported 4 times negative operating cash flow.

1.2 Ratios

ENZ has a worse Return On Assets (-31.57%) than 86.67% of its industry peers.

ENZ's Return On Equity of -45.72% is on the low side compared to the rest of the industry. ENZ is outperformed by 71.43% of its industry peers.

		Industry Rank	Sector Rank
ROA	-31.57%
ROE	-45.72%
ROIC	N/A

ROA(3y)-12.64%

ROA(5y)-11.26%

ROE(3y)-18.05%

ROE(5y)-18.29%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ENZ (44.74%) is better than 74.29% of its industry peers.

In the last couple of years the Gross Margin of ENZ has grown nicely.

ENZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	44.74%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y9.93%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ENZ has been increased compared to 1 year ago.

ENZ has more shares outstanding than it did 5 years ago.

ENZ has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -5.09, we must say that ENZ is in the distress zone and has some risk of bankruptcy.

ENZ's Altman-Z score of -5.09 is on the low side compared to the rest of the industry. ENZ is outperformed by 87.62% of its industry peers.

ENZ has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

ENZ has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. ENZ outperforms 84.76% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.09

ROIC/WACCN/A

WACC9.89%

2.3 Liquidity

A Current Ratio of 3.04 indicates that ENZ has no problem at all paying its short term obligations.

ENZ's Current ratio of 3.04 is amongst the best of the industry. ENZ outperforms 86.67% of its industry peers.

ENZ has a Quick Ratio of 2.69. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.69, ENZ belongs to the top of the industry, outperforming 81.90% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.04
Quick Ratio	2.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ENZ have decreased strongly by -430.17% in the last year.

The Revenue for ENZ has decreased by -54.20% in the past year. This is quite bad

The Revenue for ENZ have been decreasing by -17.04% on average. This is quite bad

EPS 1Y (TTM)-430.17%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.17%

Revenue 1Y (TTM)-54.2%

Revenue growth 3Y-35.29%

Revenue growth 5Y-17.04%

Sales Q2Q%-14.3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENZ. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ENZ has a Yearly Dividend Yield of 31.87%, which is a nice return.

In the last 3 months the price of ENZ has falen by -52.09%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.

ENZ's Dividend Yield is rather good when compared to the industry average which is at 2.55. ENZ pays more dividend than 100.00% of the companies in the same industry.

Compared to an average S&P500 Dividend Yield of 2.36, ENZ pays a better dividend.

		Industry Rank	Sector Rank
Dividend Yield	31.87%

5.2 History

ENZ does not have a reliable dividend history as it only pays dividend since a couple or years.

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

DPN/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ENZO BIOCHEM INC

NYSE:ENZ (4/17/2025, 8:15:28 PM)

After market: 0.32 +0.01 (+1.98%)

0.3138

-0.07 (-17.77%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)03-17 2025-03-17/amc

Earnings (Next)06-11 2025-06-11

Inst Owners34.1%

Inst Owner Change-10.93%

Ins Owners10.57%

Ins Owner Change0%

Market Cap16.44M

Revenue(TTM)29.09M

Net Income(TTM)-21.31M

Analysts80

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	31.87%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.57
P/FCF	N/A
P/OCF	N/A
P/B	0.35
P/tB	0.35
EV/EBITDA	N/A

EPS(TTM)-0.37

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.3

FCFYN/A

OCF(TTM)-0.29

OCFYN/A

SpS0.56

BVpS0.89

TBVpS0.89

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.57%
ROE	-45.72%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	44.74%
FCFM	N/A

ROA(3y)-12.64%

ROA(5y)-11.26%

ROE(3y)-18.05%

ROE(5y)-18.29%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y9.93%

F-Score3

Asset Turnover0.43

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	57.14%
Cap/Sales	2.69%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.04
Quick Ratio	2.69
Altman-Z	-5.09

F-Score3

WACC9.89%

ROIC/WACCN/A

Cap/Depr(3y)89.52%

Cap/Depr(5y)102.77%

Cap/Sales(3y)7.08%

Cap/Sales(5y)5.57%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-430.17%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.17%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-54.2%

Revenue growth 3Y-35.29%

Revenue growth 5Y-17.04%

Sales Q2Q%-14.3%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y77.33%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y42.85%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y39.68%

OCF growth 3YN/A

OCF growth 5YN/A

ENZO BIOCHEM INC / ENZ FAQ

What is the ChartMill fundamental rating of ENZO BIOCHEM INC (ENZ) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENZ.

What is the valuation status of ENZO BIOCHEM INC (ENZ) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENZO BIOCHEM INC (ENZ). This can be considered as Overvalued.

How profitable is ENZO BIOCHEM INC (ENZ) stock?

ENZO BIOCHEM INC (ENZ) has a profitability rating of 1 / 10.

ENZO BIOCHEM INC (ENZ) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

ENZO BIOCHEM INC / ENZ FAQ

What is the ChartMill fundamental rating of ENZO BIOCHEM INC (ENZ) stock?

What is the valuation status of ENZO BIOCHEM INC (ENZ) stock?

How profitable is ENZO BIOCHEM INC (ENZ) stock?